<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Chemother Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Cancer Chemotherapy and Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0344-5704</issn><issn pub-type="epub">1432-0843</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8367929</article-id><article-id pub-id-type="pmcid-ver">PMC8367929.1</article-id><article-id pub-id-type="pmcaid">8367929</article-id><article-id pub-id-type="pmcaiid">8367929</article-id><article-id pub-id-type="pmid">34120234</article-id><article-id pub-id-type="doi">10.1007/s00280-021-04305-2</article-id><article-id pub-id-type="publisher-id">4305</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A minimal physiologically based pharmacokinetic model for high-dose methotrexate</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pesenti</surname><given-names initials="G">Giuseppe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Foppoli</surname><given-names initials="M">Marco</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2055-9752</contrib-id><name name-style="western"><surname>Manca</surname><given-names initials="D">Davide</given-names></name><address><email>davide.manca@polimi.it</email><uri>http://pselab.chem.polimi.it/</uri></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.4643.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0327</institution-id><institution>PSE-Lab, Process Systems Engineering Laboratory, Dipartimento di Chimica, Materiali e Ingegneria Chimica &#8220;Giulio Natta&#8221;, </institution><institution>Politecnico di Milano, </institution></institution-wrap>Piazza Leonardo da Vinci 32, 20133 Milano, Italy </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.18887.3e</institution-id><institution-id institution-id-type="ISNI">0000000417581884</institution-id><institution>Unit of Lymphoid Malignancies, Division of Onco-Hematological Medicine, Department of Onco-Hematology, </institution><institution>IRCCS San Raffaele Scientific Institute, </institution></institution-wrap>Via Olgettina 60, 20132 Milano, Italy </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>6</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2021</year></pub-date><volume>88</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">388124</issue-id><fpage>595</fpage><lpage>606</lpage><history><date date-type="received"><day>31</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>06</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>31</day><month>08</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-02-17 03:16:53.063"><day>17</day><month>02</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2021</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="280_2021_Article_4305.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">High-dose methotrexate (HDMTX) is administered for the treatment of a variety of malignant tumors. Wide intra- and inter-individual variabilities characterize the pharmacokinetics of MTX, which is mostly excreted renally. HDMTX dosages are prescribed as a function of body surface area whereas dose adjustments depending on renal function are not well defined. We develop a population pharmacokinetic model with a physiological description of renal excretion as the basis for clinical tools able to suggest model-informed dosages and support therapeutic monitoring.</p></sec><sec><title>Methods</title><p id="Par2">This article presents a minimal physiologically based pharmacokinetic (PBPK) model for HDMTX, which specifically accounts for individual characteristics such as body weight, height, gender, age, hematocrit, and serum creatinine to provide individualized predictions. The model supplies a detailed and mechanistic description of capillary and cellular exchanges between plasma, interstitial fluid, and intracellular fluid compartments, and focuses on an individualized description of renal excretion.</p></sec><sec><title>Results</title><p id="Par3">The minimal PBPK model is identified and validated with a literature dataset based on Chinese patients suffering from primary central nervous system lymphoma. A comparison with a pharmacokinetic model from the literature suggests that the proposed model provides improved predictions. Remarkably, the model does not present any significant bias in a wide range of degrees of renal function.</p></sec><sec><title>Conclusion</title><p id="Par4">Results show that model predictions can capture the wide intra- and inter-individual variability of HDMTX, and highlight the role played by the individual degree of renal function. The proposed model can be the basis for the development of clinical decision-support systems for individualized dosages and therapeutic monitoring.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Methotrexate</kwd><kwd>HDMTX</kwd><kwd>Pharmacokinetics</kwd><kwd>Minimal PBPK</kwd><kwd>Renal function</kwd></kwd-group><funding-group><award-group><funding-source><institution>Politecnico di Milano</institution></funding-source></award-group><open-access><p>Open access funding provided by Politecnico di Milano within the CRUI-CARE Agreement.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Methotrexate (MTX) is an antifolate drug used to treat auto-immune disorders and in cancer chemotherapy. High-dose methotrexate (HDMTX) consists of doses higher than 500&#8211;1000&#160;mg/m<sup>2</sup> [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. HDMTX treats a variety of malignant tumors, which include primary central nervous system lymphoma (PCNSL), osteosarcoma, and acute lymphoblastic leukemia [<xref ref-type="bibr" rid="CR3">3</xref>]. HDMTX is used to extend the exposure duration, overcome the mechanisms of resistance to MTX [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], and penetrate the blood&#8211;brain barrier [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par6">The administration of HDMTX is characterized by a very large intra- and inter-individual variability [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>] and is associated with toxic side effects, with a reported incidence of HDMTX-induced nephrotoxicity that goes from 1.8% [<xref ref-type="bibr" rid="CR10">10</xref>] to 10.7% [<xref ref-type="bibr" rid="CR11">11</xref>]. While there are several treatment protocols for each tumor type, they usually prescribe predetermined HDMTX dosages per square meter of body surface area (BSA) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par7">MTX is mostly excreted through the kidneys [<xref ref-type="bibr" rid="CR15">15</xref>] with creatinine clearance (CrCl) being a strong determinant of methotrexate overall clearance [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Renal dysfunction leads to delayed MTX elimination and elevated plasma levels [<xref ref-type="bibr" rid="CR10">10</xref>]. Despite this, adjustments for renal function are usually limited to the definition of cut-off values of either CrCl or glomerular filtration rate (GFR) for dose reduction or omission [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Abrey [<xref ref-type="bibr" rid="CR12">12</xref>] and Joerger and coauthors [<xref ref-type="bibr" rid="CR16">16</xref>] report that uniform HDMTX dosing regimens are still lacking in the case of PCNSL, and suggest the introduction of personalized dosages to account for patient age, gender, and renal clearance, as they could significantly improve HDMTX treatment.</p><p id="Par8">Few approaches to HDMTX dose adjustment have been published in the literature. Pignon et al. [<xref ref-type="bibr" rid="CR18">18</xref>] proposed a dose adjustment approach to be performed during each 8-h cycle. Similarly, Evans et al. [<xref ref-type="bibr" rid="CR19">19</xref>] showed that, in children with acute lymphoblastic leukemia, dose adjustments after 8&#160;h of a 24&#160;h MTX infusion lead to improved outcomes. Joerger et al. [<xref ref-type="bibr" rid="CR9">9</xref>] proposed a dosing algorithm that uses the value of MTX concentration 24&#160;h after the start of the first treatment cycle to adjust individual MTX doses in the following treatment cycles.</p><p id="Par9">To the best of our knowledge, a decision-support tool capable of suggesting individualized HDMTX dosages for clinical use was not published in the literature. Accordingly, this article focuses on physiologically based pharmacokinetic (PBPK) modeling as the basis to develop that decision-support tool. Such a tool would also be suitable to support HDMTX therapeutic monitoring [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par10">In 1970, Bischoff et al. [<xref ref-type="bibr" rid="CR21">21</xref>] developed a remarkable pharmacokinetic model of methotrexate for mice, whose parameters attempted to maintain a good consistency with physiology. Then Zaharko et al. [<xref ref-type="bibr" rid="CR22">22</xref>], Bischoff et al. [<xref ref-type="bibr" rid="CR23">23</xref>], and Dedrick et al. [<xref ref-type="bibr" rid="CR24">24</xref>] published developments of the same PBPK model for mice, other mammals, and humans. More recently, Ogungbenro et al. [<xref ref-type="bibr" rid="CR25">25</xref>] proposed a methotrexate PBPK model for children and adults. However, these models do not account for individual characteristics such as body weight, height, gender, age, and degree of renal function, and their predictions of MTX pharmacokinetics can be directly applied only to a reference patient with standard body features.</p><p id="Par11">We apply the general modeling approach proposed by Cao and Jusko [<xref ref-type="bibr" rid="CR26">26</xref>] and present a new minimal PBPK model for the administration of intravenous HDMTX to adult patients that can account for individual characteristics such as body weight, height, gender, age, hematocrit, and renal function.</p><p id="Par12">Model parameters are assigned as much as possible a priori and are functions of individual characteristics. The remaining parameters (which cannot be assigned a priori) are evaluated numerically via a non-linear regression against a literature dataset of patients suffering from PCNSL and via a bootstrap analysis. Our model adopts a population-PK approach, and the regressed parameters are assumed to constant for the whole population described.</p><p id="Par13">The model devotes special attention to renal filtration. Consequently, it can be applied also to patients with reduced renal function. This approach allows improving the understanding of MTX pharmacokinetics, identifying the characteristics of peculiar populations, and refining the predictions of individual MTX pharmacokinetics.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Mathematical model</title><p id="Par14">Figure <xref rid="Fig1" ref-type="fig">1</xref> shows the overall structure of our minimal PBPK model, which was implemented in MATLAB R2020b (The MathWorks, Natick, MA, US). The model adopts the general minimal PBPK approach proposed by Cao and Jusko [<xref ref-type="bibr" rid="CR26">26</xref>] and describes two lumped compartments for interstitial fluid (ISF) and intracellular fluid (ICF). The plasma circulation of the drug is described by dividing plasma into the renal circulatory system (RCS), the hepatic circulatory system (HCS), and the remaining part of the global circulatory system (CS). Each compartment is assumed homogeneous [<xref ref-type="bibr" rid="CR27">27</xref>] so that in the generic compartment <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$j$$\end{document}</tex-math><mml:math id="M2"><mml:mi>j</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq1.gif"/></alternatives></inline-formula> with volume <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{j}$$\end{document}</tex-math><mml:math id="M4"><mml:msub><mml:mi>V</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq2.gif"/></alternatives></inline-formula>, the drug concentration <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{j}$$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mi>c</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq3.gif"/></alternatives></inline-formula> can be calculated as <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{j} = {{m_{j} } \mathord{\left/ {\vphantom {{m_{j} } {V_{j} }}} \right. \kern-\nulldelimiterspace} {V_{j} }}$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true">/</mml:mo></mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq4.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$m_{j}$$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mi>m</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq5.gif"/></alternatives></inline-formula> is the amount of drug.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Structure of the minimal PBPK model. The rectangles represent the compartments of the model: three plasma compartments (dark orange), the lumped ISF compartment (mustard), and the lumped ICF compartment (cyan). The arrows describe the drug flows, <italic toggle="yes">i.e.</italic> administration, exchange between compartments, metabolism, and excretion (colour figure online)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="280_2021_4305_Fig1_HTML.jpg"/></fig></p><p id="Par15">The following system of ordinary differential equations (Eqs. <xref rid="Equ1" ref-type="">1</xref>&#8211;<xref rid="Equ5" ref-type="">5</xref>) mathematically describes the drug material balances in the five model compartments (i.e. CS, RCS, HCS, ISF, and ICF) of Fig. <xref rid="Fig1" ref-type="fig">1</xref>:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dm_{{CS}} }}{{dt}}\; = \;\dot{m}_{{IV}} - Q_{{CS \leftrightarrow RCS}} c_{{CS}} + Q_{{CS \leftrightarrow RCS}} c_{{RCS}} - Q_{{CS \leftrightarrow HCS}} c_{{CS}} + Q_{{CS \leftrightarrow HCS}} c_{{HCS}} - \dot{m}_{{CS \to ISF}} + \dot{m}_{{ISF \to CS}}$$\end{document}</tex-math><mml:math id="M12" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mspace width="0.277778em"/><mml:mo>=</mml:mo><mml:mspace width="0.277778em"/><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">IV</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>R</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>R</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">HCS</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ1.gif"/></alternatives></disp-formula><disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dm_{RCS} }}{dt} = Q_{CS \leftrightarrow RCS} c_{CS} - Q_{CS \leftrightarrow RCS} c_{RCS} - \dot{m}_{excretion}^{renal} ,$$\end{document}</tex-math><mml:math id="M14" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>R</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>R</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">excretion</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">renal</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ2.gif"/></alternatives></disp-formula><disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dm_{HCS} }}{dt} = Q_{CS \leftrightarrow HCS} c_{CS} - Q_{CS \leftrightarrow HCS} c_{HCS} - \dot{m}_{elimination}^{hepatic} ,$$\end{document}</tex-math><mml:math id="M16" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="italic">HCS</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">HCS</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">elimination</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">hepatic</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ3.gif"/></alternatives></disp-formula><disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dm_{ISF} }}{dt} = \dot{m}_{CS \to ISF} - \dot{m}_{ISF \to CS} - \dot{m}_{ISF \to ICF} + \dot{m}_{ICF \to ISF} ,$$\end{document}</tex-math><mml:math id="M18" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ4.gif"/></alternatives></disp-formula><disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dm_{ICF} }}{dt} = \dot{m}_{ISF \to ICF} - \dot{m}_{ICF \to ISF} ,$$\end{document}</tex-math><mml:math id="M20" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ5.gif"/></alternatives></disp-formula>
where <inline-formula id="IEq6"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{IV}$$\end{document}</tex-math><mml:math id="M22"><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">IV</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq6.gif"/></alternatives></inline-formula> is the MTX flow administered intravenously at each instant, <inline-formula id="IEq7"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{CS \leftrightarrow RCS}$$\end{document}</tex-math><mml:math id="M24"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>R</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq7.gif"/></alternatives></inline-formula> and <inline-formula id="IEq8"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{CS \leftrightarrow HCS}$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq8.gif"/></alternatives></inline-formula> are the plasma flow rates exchanged with RCS and HCS, <inline-formula id="IEq9"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M28"><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq9.gif"/></alternatives></inline-formula> and <inline-formula id="IEq10"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M30"><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq10.gif"/></alternatives></inline-formula> represent the MTX flow rates exchanged between CS and ISF at the capillary level, <inline-formula id="IEq11"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ISF \to ICF}$$\end{document}</tex-math><mml:math id="M32"><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq11.gif"/></alternatives></inline-formula> and <inline-formula id="IEq12"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ICF \to ISF}$$\end{document}</tex-math><mml:math id="M34"><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq12.gif"/></alternatives></inline-formula> are the MTX flow rates entering and leaving ICF due to cellular exchange with ISF, <inline-formula id="IEq13"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{excretion}^{renal}$$\end{document}</tex-math><mml:math id="M36"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">excretion</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">renal</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq13.gif"/></alternatives></inline-formula> is the renal excretion, and <inline-formula id="IEq14"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{elimination}^{hepatic}$$\end{document}</tex-math><mml:math id="M38"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">elimination</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">hepatic</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq14.gif"/></alternatives></inline-formula> is the hepatic metabolic elimination. The model describes the capillary exchange between ISF and the plasma compartments as if it took place only within the global CS compartment.</p></sec><sec id="Sec4"><title>Plasma, ISF, and ICF volumes</title><p id="Par17">Assuming that the body volumes grow linearly with body weight, the reference values of 5.3 L blood volume for a 73&#160;kg man and 3.9 L for a 60&#160;kg woman [<xref ref-type="bibr" rid="CR28">28</xref>] allow inferring that men and women have 72&#160;mL and 65&#160;mL of blood per kg, respectively. Total plasma volume can be easily related to total blood volume by subtracting the hematocrit (HCT). The RCS and HCS plasma volumes are estimated, respectively, as 2% and 10% of total plasma [<xref ref-type="bibr" rid="CR28">28</xref>]. Consequently, the CS plasma volume is the remaining fraction of plasma volume. The extracellular fluid (ECF) and ICF volumes are likewise estimated using as reference the average ECW and ICW values from Ritz et al. [<xref ref-type="bibr" rid="CR29">29</xref>]. Finally, the ISF volume is calculated as the difference between ECF and plasma volumes.</p><p id="Par18">Notably, our model does not fit the bodily volumes, and their values are instead assigned as individualized estimates from the patient&#8217;s body weight and HCT. All the volume estimates refer to the physiological volumes of plasma, ISF, or ICF. It should be noted, however, that these values do not take into account the individual excess fat, nutrition, race, and age, and may further change according to, e.g. hydration and sodium balance.</p></sec><sec id="Sec5"><title>Plasma flow rates</title><p id="Par19">The total cardiac output (CO) <inline-formula id="IEq15"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{CO}^{plasma}$$\end{document}</tex-math><mml:math id="M40"><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">CO</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq15.gif"/></alternatives></inline-formula> (in mL/min) and the fractions of CO that reach the kidneys and the liver are estimated with the equations developed by Stader et al. [<xref ref-type="bibr" rid="CR30">30</xref>] as a function of body weight, height, gender, age, and HCT.</p></sec><sec id="Sec6"><title>Methotrexate protein binding</title><p id="Par20">MTX is affected by protein binding, <italic toggle="yes">i.e.</italic> the reversible binding between the drug and blood proteins [<xref ref-type="bibr" rid="CR31">31</xref>]. Protein binding of MTX occurs predominantly with serum albumin [<xref ref-type="bibr" rid="CR32">32</xref>] and the drug is inactive while bound.</p><p id="Par21">In plasma, reported values of MTX protein binding for healthy patients usually fall in the 42&#8211;57% interval [<xref ref-type="bibr" rid="CR31">31</xref>] and appear to decrease in patients that are ill or in remission (<italic toggle="yes">e.g.</italic> to 34&#8211;40% [<xref ref-type="bibr" rid="CR33">33</xref>]). To apply the model to patients who suffer from tumor diseases and require the administration of HDMTX, the MTX bound fraction in plasma <inline-formula id="IEq16"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{plasma}^{b}$$\end{document}</tex-math><mml:math id="M42"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow><mml:mi>b</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq16.gif"/></alternatives></inline-formula> is assumed constant and equal to 42% [<xref ref-type="bibr" rid="CR31">31</xref>]. Albumin gives rise to protein binding also in the ISF [<xref ref-type="bibr" rid="CR34">34</xref>]. Following the approach of Schmitt [<xref ref-type="bibr" rid="CR35">35</xref>], the MTX bound fraction in ISF <inline-formula id="IEq17"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ISF}^{b}$$\end{document}</tex-math><mml:math id="M44"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>b</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq17.gif"/></alternatives></inline-formula> is estimated as 28%. Therefore, the complementary MTX unbound fractions <inline-formula id="IEq18"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{plasma}^{u}$$\end{document}</tex-math><mml:math id="M46"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq18.gif"/></alternatives></inline-formula> and <inline-formula id="IEq19"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ISF}^{u}$$\end{document}</tex-math><mml:math id="M48"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq19.gif"/></alternatives></inline-formula> are 58% and 72%, respectively.</p></sec><sec id="Sec7"><title>Methotrexate renal excretion</title><p id="Par22">The main elimination route for MTX is renal excretion [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Following intravenous administration of HDMTX, about 90% of the drug leaves the body unchanged through the urine within 154&#160;h (<italic toggle="yes">i.e.</italic> almost a week) [<xref ref-type="bibr" rid="CR36">36</xref>]. MTX is filtered by the renal corpuscles of each nephron, and undergoes active secretion and active reabsorption [<xref ref-type="bibr" rid="CR15">15</xref>] as follows:<disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{excretion}^{renal} = \dot{m}_{filtration} + \dot{m}_{secretion} - \dot{m}_{reabsorption} .$$\end{document}</tex-math><mml:math id="M50" display="block"><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">excretion</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">renal</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">filtration</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ6.gif"/></alternatives></disp-formula></p><p id="Par23">Assuming that unbound MTX is freely filtered across the glomerular filtration barrier and neglecting the filtration of albumin-bound MTX, renal filtration is described as<disp-formula id="Equ7"><label>7</label><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{filtration} = Q_{GFR} c_{RCS} f_{plasma}^{u} .$$\end{document}</tex-math><mml:math id="M52" display="block"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">filtration</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">GFR</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ7.gif"/></alternatives></disp-formula></p><p id="Par24">Several equations have been developed in the literature to estimate the individual <inline-formula id="IEq20"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{GFR}$$\end{document}</tex-math><mml:math id="M54"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">GFR</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq20.gif"/></alternatives></inline-formula> from the serum creatinine levels, since obtaining experimental creatinine values from the blood is cheap and convenient. These equations correlate the blood creatinine levels to the steady-state values of <inline-formula id="IEq21"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{GFR}$$\end{document}</tex-math><mml:math id="M56"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">GFR</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq21.gif"/></alternatives></inline-formula> for a specific population, also by taking into account the body weight, height, gender, and age of the patient. In this work, we employed the CKD-EPI equation with a 4-level variable for race [<xref ref-type="bibr" rid="CR37">37</xref>], which is suitable to describe both patients with renal impairment and with normal renal function. We used the coefficients for Asians to describe Chinese patients. Additionally, the 97.5th percentile of the reference interval by the FAS equation [<xref ref-type="bibr" rid="CR38">38</xref>] was used as the upper limit to the <inline-formula id="IEq22"><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{GFR}$$\end{document}</tex-math><mml:math id="M58"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">GFR</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq22.gif"/></alternatives></inline-formula> estimates.</p><p id="Par25">Secretion and reabsorption are described as a single overall saturable process (Eqs. <xref rid="Equ8" ref-type="">8</xref> and <xref rid="Equ9" ref-type="">9</xref>) with Michaelis&#8211;Menten kinetics. The modeling of reabsorption is simplified and is expressed as a function of the drug concentration inside the plasma, similar to secretion.<disp-formula id="Equ8"><label>8</label><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{secretion} = \dot{m}_{secretion}^{max} \cdot \frac{{c_{RCS}^{u} }}{{K_{50}^{secretion} + c_{RCS}^{u} }},$$\end{document}</tex-math><mml:math id="M60" display="block"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:mo>&#183;</mml:mo><mml:mfrac><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ8.gif"/></alternatives></disp-formula><disp-formula id="Equ9"><label>9</label><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{reabsorption} = \dot{m}_{reabsorption}^{max} \cdot \frac{{c_{RCS}^{u} }}{{K_{50}^{reabsorption} + c_{RCS}^{u} }}.$$\end{document}</tex-math><mml:math id="M62" display="block"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:mo>&#183;</mml:mo><mml:mfrac><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ9.gif"/></alternatives></disp-formula></p><p id="Par26">The Michaelis constants <inline-formula id="IEq23"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{secretion}$$\end{document}</tex-math><mml:math id="M64"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq23.gif"/></alternatives></inline-formula> and <inline-formula id="IEq24"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{reabsorption}$$\end{document}</tex-math><mml:math id="M66"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq24.gif"/></alternatives></inline-formula> are estimated as 0.1&#160;&#181;mol/L and 0.6&#160;&#181;mol/L, multiplied by <inline-formula id="IEq25"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{u,plasma}$$\end{document}</tex-math><mml:math id="M68"><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq25.gif"/></alternatives></inline-formula> [<xref ref-type="bibr" rid="CR15">15</xref>], whereas <inline-formula id="IEq26"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{secretion}^{max}$$\end{document}</tex-math><mml:math id="M70"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq26.gif"/></alternatives></inline-formula> and <inline-formula id="IEq27"><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{reabsorption}^{max}$$\end{document}</tex-math><mml:math id="M72"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq27.gif"/></alternatives></inline-formula> are assigned as 5.189 and 1.038&#160;&#181;g/min (for a reference <inline-formula id="IEq28"><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{GFR}$$\end{document}</tex-math><mml:math id="M74"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">GFR</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq28.gif"/></alternatives></inline-formula> of 100&#160;mL/min, assuming a proportionality to <inline-formula id="IEq29"><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{GFR}$$\end{document}</tex-math><mml:math id="M76"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">GFR</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq29.gif"/></alternatives></inline-formula>). The overall MTX renal clearance described exceeds that of creatinine by up to 15% in the 0.1&#8211;0.4&#160;&#181;mol/L range and is consistent with the experimental trends [<xref ref-type="bibr" rid="CR15">15</xref>]. As MTX concentration increases, secretion and reabsorption reach saturation and their relative contribution becomes smaller, so that renal clearance approaches creatinine clearance and the glomerular filtration rate.</p></sec><sec id="Sec8"><title>Methotrexate hepatic elimination</title><p id="Par27">MTX is affected by uptake into the hepatocytes of the liver, where it is metabolized into its major metabolite, 7-hydroxymethotrexate (7-OH-MTX), and is also affected by biliary secretion. In the intestinal tract, MTX can be reabsorbed into the systemic circulation, excreted through the feces, or hydrolyzed to 2,4-diamino-N10-methylpteroic acid (DAMPA), a minor metabolite [<xref ref-type="bibr" rid="CR39">39</xref>]. These routes represent a minor contribution to the overall MTX elimination [<xref ref-type="bibr" rid="CR40">40</xref>], which does not appear correlated to biomarkers of liver function [<xref ref-type="bibr" rid="CR41">41</xref>]. In the case of HDMTX, since these routes depend mostly on saturable processes, it is likely that their relative importance decreases further. Hepatic processes are therefore described with a simplified approach, which neglects the enterohepatic circulation and assumes that MTX affected by hepatic clearance is immediately either metabolized into 7-OH-MTX or secreted into the bile and metabolized into DAMPA or eventually excreted through the feces (Eq. <xref rid="Equ10" ref-type="">10</xref>).<disp-formula id="Equ10"><label>10</label><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{elimination}^{hepatic} = Q_{clearance}^{hepatic} c_{HCS}^{u} .$$\end{document}</tex-math><mml:math id="M78" display="block"><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">elimination</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">hepatic</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">clearance</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">hepatic</mml:mi></mml:mrow></mml:msubsup><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">HCS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ10.gif"/></alternatives></disp-formula></p><p id="Par28">The hepatic clearance is estimated as 4% of the GFR so that the overall hepatic elimination represents about 4% of the overall MTX clearance, approximately accounting for a 3% contribution from 7-OH-MTX metabolism [<xref ref-type="bibr" rid="CR40">40</xref>] and 1% from DAMPA metabolism and excretion through feces [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec9"><title>Methotrexate capillary exchange</title><p id="Par29">MTX reaches the interstitial fluid through extravasation from the blood vessels at the capillary level. We describe capillary exchange in all tissues as generally permeability-limited (or diffusion-limited) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. We assume that MTX is exchanged only by passive transport mechanisms, <italic toggle="yes">i.e.</italic> simple diffusion, according to the unbound <inline-formula id="IEq30"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CS}^{u}$$\end{document}</tex-math><mml:math id="M80"><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq30.gif"/></alternatives></inline-formula> and <inline-formula id="IEq31"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{ISF}^{u}$$\end{document}</tex-math><mml:math id="M82"><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq31.gif"/></alternatives></inline-formula> concentrations:<disp-formula id="Equ11"><label>11</label><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{gathered} \dot{m}_{CS \to ISF} = K_{CS \to ISF} c_{CS}^{u} , \hfill \\ \dot{m}_{ISF \to CS} = K_{ISF \to CS} c_{ISF}^{u} . \hfill \\ \end{gathered}$$\end{document}</tex-math><mml:math id="M84" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow/></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ11.gif"/></alternatives></disp-formula></p><p id="Par30">The exchange constants <inline-formula id="IEq32"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M86"><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq32.gif"/></alternatives></inline-formula> and <inline-formula id="IEq33"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M88"><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq33.gif"/></alternatives></inline-formula> represent the permeability-surface area product <inline-formula id="IEq34"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$PS$$\end{document}</tex-math><mml:math id="M90"><mml:mrow><mml:mi mathvariant="italic">PS</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq34.gif"/></alternatives></inline-formula> (mL/min) and are estimated with Eq. (<xref rid="Equ12" ref-type="">12</xref>) from their corresponding intensive constants <inline-formula id="IEq35"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M92"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq35.gif"/></alternatives></inline-formula> and <inline-formula id="IEq36"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M94"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq36.gif"/></alternatives></inline-formula> (min<sup>&#8722;1</sup>).<disp-formula id="Equ12"><label>12</label><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{gathered} K_{CS \to ISF} = k_{CS \to ISF} V_{ISF} , \hfill \\ K_{ISF \to CS} = k_{ISF \to CS} V_{ISF} . \hfill \\ \end{gathered}$$\end{document}</tex-math><mml:math id="M96" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow/></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ12.gif"/></alternatives></disp-formula></p><p id="Par31">Concerning the exchange between CS and ISF, at steady-state <inline-formula id="IEq37"><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{CS \to ISF} = \dot{m}_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M98"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq37.gif"/></alternatives></inline-formula> and, therefore,<disp-formula id="Equ13"><label>13</label><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{c_{ISF}^{u} }}{{c_{CS}^{u} }} = \frac{{K_{CS \to ISF} }}{{K_{ISF \to CS} }} = \frac{{k_{CS \to ISF} }}{{k_{ISF \to CS} }},$$\end{document}</tex-math><mml:math id="M100" display="block"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ13.gif"/></alternatives></disp-formula><disp-formula id="Equ14"><label>14</label><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{c_{ISF} }}{{c_{plasma} }} = \frac{{f_{plasma}^{u} }}{{f_{ISF}^{u} }}\frac{{k_{CS \to ISF} }}{{k_{ISF \to CS} }}.$$\end{document}</tex-math><mml:math id="M102" display="block"><mml:mrow><mml:mfrac><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:mfrac><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ14.gif"/></alternatives></disp-formula></p><p id="Par32">By defining the tissue partition coefficient as <inline-formula id="IEq38"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{c_{ISF} } \mathord{\left/ {\vphantom {{c_{ISF} } {c_{plasma} }}} \right. \kern-\nulldelimiterspace} {c_{plasma} }}$$\end{document}</tex-math><mml:math id="M104"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">/</mml:mo></mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq38.gif"/></alternatives></inline-formula>, its value is directly related with the <inline-formula id="IEq39"><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{k_{CS \to ISF} } \mathord{\left/ {\vphantom {{k_{CS \to ISF} } {k_{ISF \to CS} }}} \right. \kern-\nulldelimiterspace} {k_{ISF \to CS} }}$$\end{document}</tex-math><mml:math id="M106"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">/</mml:mo></mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq39.gif"/></alternatives></inline-formula> ratio through <inline-formula id="IEq40"><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{plasma}^{u}$$\end{document}</tex-math><mml:math id="M108"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq40.gif"/></alternatives></inline-formula> and <inline-formula id="IEq41"><alternatives><tex-math id="M109">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ISF}^{u}$$\end{document}</tex-math><mml:math id="M110"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq41.gif"/></alternatives></inline-formula> (Eq. <xref rid="Equ14" ref-type="">14</xref>). This equivalence allows expressing for both <inline-formula id="IEq42"><alternatives><tex-math id="M111">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M112"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq42.gif"/></alternatives></inline-formula> and <inline-formula id="IEq43"><alternatives><tex-math id="M113">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M114"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq43.gif"/></alternatives></inline-formula> the same physiological restrictions applied by Cao, Jusko [<xref ref-type="bibr" rid="CR26">26</xref>] concerning CO. Furthermore, Eq. (<xref rid="Equ13" ref-type="">13</xref>) shows that the <inline-formula id="IEq44"><alternatives><tex-math id="M115">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{k_{CS \to ISF} } \mathord{\left/ {\vphantom {{k_{CS \to ISF} } {k_{ISF \to CS} }}} \right. \kern-\nulldelimiterspace} {k_{ISF \to CS} }}$$\end{document}</tex-math><mml:math id="M116"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">/</mml:mo></mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq44.gif"/></alternatives></inline-formula> ratio is related to the ratio of unbound concentrations at steady-state, which are expected to be equal [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. The values of <inline-formula id="IEq45"><alternatives><tex-math id="M117">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M118"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq45.gif"/></alternatives></inline-formula> and <inline-formula id="IEq46"><alternatives><tex-math id="M119">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M120"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq46.gif"/></alternatives></inline-formula>, which are fitted, will account for the actual degree of permeability limitation in the capillary exchange and are expected to compensate for modeling errors, <italic toggle="yes">e.g.</italic> compartment volumes and protein binding.</p></sec><sec id="Sec10"><title>Methotrexate cellular exchange</title><p id="Par33">The minimal PBPK model is extended with an ICF compartment as MTX is affected by extensive cellular uptake [<xref ref-type="bibr" rid="CR1">1</xref>]. Inside cells, methotrexate undergoes an extensive, reversible transformation from its native monoglutamate form into polyglutamate derivatives by folylpolyglutamate synthase (FPGS) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Our model does not provide an explicit description of the polyglutamate forms of methotrexate and neglects their efflux. Since Galivan [<xref ref-type="bibr" rid="CR45">45</xref>] reports an intracellular polyglutamation exceeding 90%, this value is tentatively taken as the reference value for the ICF bound fraction, described with <inline-formula id="IEq47"><alternatives><tex-math id="M121">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ICF}^{b}$$\end{document}</tex-math><mml:math id="M122"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow><mml:mi>b</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq47.gif"/></alternatives></inline-formula> and <inline-formula id="IEq48"><alternatives><tex-math id="M123">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ICF}^{u}$$\end{document}</tex-math><mml:math id="M124"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq48.gif"/></alternatives></inline-formula> of about 90% and 10%, respectively.</p><p id="Par34">We assume that the total MTX uptake <inline-formula id="IEq49"><alternatives><tex-math id="M125">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ISF \to ICF}$$\end{document}</tex-math><mml:math id="M126"><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq49.gif"/></alternatives></inline-formula> can be sufficiently described with a single Michaelis&#8211;Menten equation, representing the RFC (<italic toggle="yes">i.e.</italic> Reduced Folate Carrier [<xref ref-type="bibr" rid="CR1">1</xref>]) transport system, as a function of the unbound ISF concentration:<disp-formula id="Equ15"><label>15</label><alternatives><tex-math id="M127">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ISF \to ICF} = \dot{m}_{ISF \to ICF}^{max} \cdot \frac{{c_{ISF}^{u} }}{{K_{50}^{RFC,influx} + c_{ISF}^{u} }}.$$\end{document}</tex-math><mml:math id="M128" display="block"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:mo>&#183;</mml:mo><mml:mfrac><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ15.gif"/></alternatives></disp-formula></p><p id="Par35">Similarly, Eq. (<xref rid="Equ16" ref-type="">16</xref>) describes the total MTX efflux <inline-formula id="IEq50"><alternatives><tex-math id="M129">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ICF \to ISF}$$\end{document}</tex-math><mml:math id="M130"><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq50.gif"/></alternatives></inline-formula> as a function of unbound ICF concentration:<disp-formula id="Equ16"><label>16</label><alternatives><tex-math id="M131">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ICF \to ISF} = \dot{m}_{ICF \to ISF}^{max} \cdot \frac{{c_{ICF}^{u} }}{{K_{50}^{RFC,efflux} + c_{ICF}^{u} }}.$$\end{document}</tex-math><mml:math id="M132" display="block"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:mo>&#183;</mml:mo><mml:mfrac><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ16.gif"/></alternatives></disp-formula></p><p id="Par36">The Michaelis influx constant is approximately equal to 5&#160;&#181;M [<xref ref-type="bibr" rid="CR46">46</xref>], multiplied by <inline-formula id="IEq51"><alternatives><tex-math id="M133">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ISF}^{u}$$\end{document}</tex-math><mml:math id="M134"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq51.gif"/></alternatives></inline-formula>, and since RFC efflux shares significant similarities with RFC uptake [<xref ref-type="bibr" rid="CR46">46</xref>], <inline-formula id="IEq52"><alternatives><tex-math id="M135">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{RFC,efflux}$$\end{document}</tex-math><mml:math id="M136"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq52.gif"/></alternatives></inline-formula> is assumed to be equal to <inline-formula id="IEq53"><alternatives><tex-math id="M137">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{RFC,influx}$$\end{document}</tex-math><mml:math id="M138"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq53.gif"/></alternatives></inline-formula>.</p><p id="Par37">Finally, <inline-formula id="IEq54"><alternatives><tex-math id="M139">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M140"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq54.gif"/></alternatives></inline-formula> and <inline-formula id="IEq55"><alternatives><tex-math id="M141">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M142"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq55.gif"/></alternatives></inline-formula> are the maximum rates exchanged between ISF and ICF and are assumed proportional to the total ICF volume (Eq. <xref rid="Equ17" ref-type="">17</xref>).<disp-formula id="Equ17"><label>17</label><alternatives><tex-math id="M143">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{gathered} \dot{m}_{ISF \to ICF}^{max} = k_{ISF \to ICF}^{max} V_{ICF} , \hfill \\ \dot{m}_{ICF \to ISF}^{max} = k_{ICF \to ISF}^{max} V_{ICF} , \hfill \\ \end{gathered}$$\end{document}</tex-math><mml:math id="M144" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mrow/><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow/></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ17.gif"/></alternatives></disp-formula>
where the intensive parameters <inline-formula id="IEq56"><alternatives><tex-math id="M145">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M146"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq56.gif"/></alternatives></inline-formula> and <inline-formula id="IEq57"><alternatives><tex-math id="M147">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M148"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq57.gif"/></alternatives></inline-formula> (min<sup>&#8722;1</sup>) are fitted.</p><p id="Par39">Table <xref rid="Tab1" ref-type="table">1</xref> summarizes all the model parameters, detailing whether (i) they have a fixed assigned value, (ii) are estimated according to the individual features of the patient (&#8220;Individualized&#8221;), or (iii) are determined via a regression procedure (&#8220;Fitted&#8221;).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>List of model parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Description</th><th align="left" colspan="1" rowspan="1">Value</th><th align="left" colspan="1" rowspan="1">Units</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq75"><alternatives><tex-math id="M149">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{plasma}$$\end{document}</tex-math><mml:math id="M150"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq75.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Total plasma volume</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq76"><alternatives><tex-math id="M151">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{CS}$$\end{document}</tex-math><mml:math id="M152"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq76.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">CS plasma volume</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq77"><alternatives><tex-math id="M153">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{RCS}$$\end{document}</tex-math><mml:math id="M154"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">RCS</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq77.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">RCS plasma volume</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq78"><alternatives><tex-math id="M155">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{HCS}$$\end{document}</tex-math><mml:math id="M156"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">HCS</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq78.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">HCS plasma volume</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq79"><alternatives><tex-math id="M157">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{ISF}$$\end{document}</tex-math><mml:math id="M158"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq79.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">ISF volume</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq80"><alternatives><tex-math id="M159">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{ICF}$$\end{document}</tex-math><mml:math id="M160"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq80.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">ICF plasma volume</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq81"><alternatives><tex-math id="M161">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{CO}^{plasma}$$\end{document}</tex-math><mml:math id="M162"><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">CO</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq81.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Plasma cardiac output</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq82"><alternatives><tex-math id="M163">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{CS \leftrightarrow RCS}^{plasma}$$\end{document}</tex-math><mml:math id="M164"><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>R</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq82.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Renal plasma flow (through renal arteries)</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq83"><alternatives><tex-math id="M165">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{CS \leftrightarrow HCS}^{plasma}$$\end{document}</tex-math><mml:math id="M166"><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8596;</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq83.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Hepatic plasma flow (through the hepatic vein)</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq84"><alternatives><tex-math id="M167">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{plasma}^{b}$$\end{document}</tex-math><mml:math id="M168"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow><mml:mi>b</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq84.gif"/></alternatives></inline-formula>/<inline-formula id="IEq85"><alternatives><tex-math id="M169">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{plasma}^{u}$$\end{document}</tex-math><mml:math id="M170"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq85.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Bound/unbound MTX fraction in plasma</td><td align="left" colspan="1" rowspan="1">0.42/0.58</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq86"><alternatives><tex-math id="M171">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ISF}^{b}$$\end{document}</tex-math><mml:math id="M172"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>b</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq86.gif"/></alternatives></inline-formula>/<inline-formula id="IEq87"><alternatives><tex-math id="M173">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ISF}^{u}$$\end{document}</tex-math><mml:math id="M174"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ISF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq87.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Bound/unbound MTX fraction in ISF</td><td align="left" colspan="1" rowspan="1">0.28/0.72</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq88"><alternatives><tex-math id="M175">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ICF}^{b}$$\end{document}</tex-math><mml:math id="M176"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow><mml:mi>b</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq88.gif"/></alternatives></inline-formula>/<inline-formula id="IEq89"><alternatives><tex-math id="M177">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ICF}^{u}$$\end{document}</tex-math><mml:math id="M178"><mml:msubsup><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ICF</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq89.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Bound/unbound MTX fraction in ICF</td><td align="left" colspan="1" rowspan="1">0.9/0.1</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq90"><alternatives><tex-math id="M179">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{GFR}$$\end{document}</tex-math><mml:math id="M180"><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">GFR</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq90.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Glomerular filtration rate</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq91"><alternatives><tex-math id="M181">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{secretion}$$\end{document}</tex-math><mml:math id="M182"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq91.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Secretion Michaelis constant</td><td align="left" colspan="1" rowspan="1">1.3179E-04</td><td align="left" colspan="1" rowspan="1">mg/mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq92"><alternatives><tex-math id="M183">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{secretion}^{max}$$\end{document}</tex-math><mml:math id="M184"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">secretion</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq92.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Maximum rate of secretion</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">&#181;g/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq93"><alternatives><tex-math id="M185">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{reabsorption}$$\end{document}</tex-math><mml:math id="M186"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq93.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Reabsorption Michaelis constant</td><td align="left" colspan="1" rowspan="1">2.6358E-05</td><td align="left" colspan="1" rowspan="1">mg/mL</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq94"><alternatives><tex-math id="M187">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{reabsorption}^{max}$$\end{document}</tex-math><mml:math id="M188"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">reabsorption</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq94.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Maximum rate of reabsorption</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">&#181;g/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq95"><alternatives><tex-math id="M189">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Q_{clerance}^{hepatic}$$\end{document}</tex-math><mml:math id="M190"><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">clerance</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">hepatic</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq95.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Overall hepatic clearance</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq96"><alternatives><tex-math id="M191">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M192"><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq96.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">CS&#8201;&#8594;&#8201;ISF exchange constant</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq97"><alternatives><tex-math id="M193">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M194"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq97.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">CS&#8201;&#8594;&#8201;ISF intensive exchange constant</td><td align="left" colspan="1" rowspan="1">Fitted</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq98"><alternatives><tex-math id="M195">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M196"><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq98.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">ISF&#8201;&#8594;&#8201;CS exchange constant</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mL/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq99"><alternatives><tex-math id="M197">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M198"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq99.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">ISF&#8201;&#8594;&#8201;CS intensive exchange constant</td><td align="left" colspan="1" rowspan="1">Fitted</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq100"><alternatives><tex-math id="M199">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{RFC,influx}$$\end{document}</tex-math><mml:math id="M200"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq100.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Cellular influx Michaelis constant</td><td align="left" colspan="1" rowspan="1">3.6</td><td align="left" colspan="1" rowspan="1">&#181;mol/L</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq101"><alternatives><tex-math id="M201">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M202"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq101.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Maximum rate of cellular uptake</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mg/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq102"><alternatives><tex-math id="M203">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M204"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq102.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Intensive maximum cellular uptake constant</td><td align="left" colspan="1" rowspan="1">Fitted</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq103"><alternatives><tex-math id="M205">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{50}^{RFC,efflux}$$\end{document}</tex-math><mml:math id="M206"><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>F</mml:mi><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq103.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Cellular efflux Michaelis constant</td><td align="left" colspan="1" rowspan="1">3.6</td><td align="left" colspan="1" rowspan="1">&#181;mol/L</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq104"><alternatives><tex-math id="M207">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\dot{m}_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M208"><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq104.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Maximum rate of cellular efflux</td><td align="left" colspan="1" rowspan="1">Individualized</td><td align="left" colspan="1" rowspan="1">mg/min</td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq105"><alternatives><tex-math id="M209">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M210"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq105.gif"/></alternatives></inline-formula></td><td align="left" colspan="1" rowspan="1">Intensive maximum cellular efflux constant</td><td align="left" colspan="1" rowspan="1">Fitted</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec11"><title>Case study</title><p id="Par40">We employed the experimental dataset of Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>] to perform the model identification and validation. The dataset collects the individual information of 98 Chinese patients with PCNSL who underwent intravenous HDMTX treatment in Beijing Tiantan Hospital. A preliminary screening selected only the adults aged&#8201;&#8805;&#8201;18 y of the study and allowed removing three outlier patients, <italic toggle="yes">i.e.</italic> patients labeled 580.1, 613.3, and 614.1, who showed plasma MTX concentrations higher than 0.2&#160;&#181;M after more than 150&#160;h following the administration of a 1.5&#8211;1.6&#160;g dose. This led to the selection of 84 patients.</p><p id="Par41">For each patient, Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>] collected the body weight (44&#8211;100&#160;kg), height (146&#8211;181&#160;cm), gender (43 men, 41 women), age (27&#8211;83 y), data on comedications, as well as the results of laboratory tests such as hematocrit, serum creatinine, blood albumin, and total blood proteins. Most of the reported data were measured periodically. The population presents a wide range of degrees of renal function, as their estimated GFR values range from 35&#160;mL/min to 162&#160;mL/min (39&#8211;150&#160;mL/min/1.73m<sup>2</sup>), including patients with mild/moderate renal impairment.</p><p id="Par42">Patients received from 1 to 17 administrations of the drug, over a time period from 36&#160;h to 352 d, for a grand total of 396 infusions. The dataset reports the amount of each administration (1&#8211;9&#160;g, or 0.62&#8211;5.16&#160;g/m<sup>2</sup>), the time of administration, and the infusion duration (0.32&#8211;7.71&#160;h). We assume that the administered infusion rate was constant over the reported duration. Following administration, Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>] measured plasma MTX concentrations every day, until the concentration fell below 0.05&#160;&#181;M, yielding 657 measurements (<inline-formula id="IEq58"><alternatives><tex-math id="M211">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{tot}^{exp}$$\end{document}</tex-math><mml:math id="M212"><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">tot</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">exp</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq58.gif"/></alternatives></inline-formula>).</p><p id="Par43">As discussed in the Methods section, the number of adaptive population parameters was kept as low as possible (<inline-formula id="IEq59"><alternatives><tex-math id="M213">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M214"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq59.gif"/></alternatives></inline-formula>, <inline-formula id="IEq60"><alternatives><tex-math id="M215">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M216"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq60.gif"/></alternatives></inline-formula>, <inline-formula id="IEq61"><alternatives><tex-math id="M217">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M218"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq61.gif"/></alternatives></inline-formula>, <inline-formula id="IEq62"><alternatives><tex-math id="M219">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M220"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq62.gif"/></alternatives></inline-formula>). Their value is computed numerically (<italic toggle="yes">i.e.</italic> identified) through a non-linear regression procedure (Eq. <xref rid="Equ18" ref-type="">18</xref>, see [<xref ref-type="bibr" rid="CR27">27</xref>]) against a subset of the experimental data [<xref ref-type="bibr" rid="CR41">41</xref>] comprising 56 adult patients from Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>]. These patients and the remaining twenty-eight patients feature similar distributions of body weight, gender, GFR, total blood proteins, and hematocrit.<disp-formula id="Equ18"><label>18</label><alternatives><tex-math id="M221">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathop {\min }\limits_{{k_{CS \to ISF} ,k_{ISF \to CS} ,k_{ISF \to ICF}^{max} ,k_{ICF \to ISF}^{max} }} \left\{ {ObjFun} \right\}.$$\end{document}</tex-math><mml:math id="M222" display="block"><mml:mrow><mml:munder><mml:mo movablelimits="false">min</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:munder><mml:mfenced close="}" open="{"><mml:mrow><mml:mi mathvariant="italic">ObjFun</mml:mi></mml:mrow></mml:mfenced><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ18.gif"/></alternatives></disp-formula></p><p id="Par44">We estimated <inline-formula id="IEq63"><alternatives><tex-math id="M223">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ObjFun$$\end{document}</tex-math><mml:math id="M224"><mml:mrow><mml:mi mathvariant="italic">ObjFun</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq63.gif"/></alternatives></inline-formula>, the objective function, as the mean squared logarithmic errors between each experimental point <inline-formula id="IEq64"><alternatives><tex-math id="M225">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CS,ij}^{exp}$$\end{document}</tex-math><mml:math id="M226"><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">exp</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq64.gif"/></alternatives></inline-formula> and their corresponding simulated value <inline-formula id="IEq65"><alternatives><tex-math id="M227">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CS,ij}^{sim}$$\end{document}</tex-math><mml:math id="M228"><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">sim</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq65.gif"/></alternatives></inline-formula>:<disp-formula id="Equ19"><label>19</label><alternatives><tex-math id="M229">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ObjFun = \frac{1}{{N_{tot}^{exp} }}\sum\limits_{i = 1}^{{N_{P} }} {\sum\limits_{j = 1}^{{N_{i}^{exp} }} {\left[ {\log \left( {c_{CS,ij}^{exp} } \right) - \log \left( {c_{CS,ij}^{sim} } \right)} \right]^{2} } } .$$\end{document}</tex-math><mml:math id="M230" display="block"><mml:mrow><mml:mi>O</mml:mi><mml:mi>b</mml:mi><mml:mi>j</mml:mi><mml:mi>F</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi mathvariant="italic">tot</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">exp</mml:mi></mml:mrow></mml:msubsup></mml:mfrac><mml:munderover><mml:mo movablelimits="false">&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:munderover><mml:mo movablelimits="false">&#8721;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msubsup><mml:mi>N</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">exp</mml:mi></mml:mrow></mml:msubsup></mml:munderover><mml:msup><mml:mfenced close="]" open="["><mml:mrow><mml:mo>log</mml:mo><mml:mfenced close=")" open="("><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">exp</mml:mi></mml:mrow></mml:msubsup></mml:mfenced><mml:mo>-</mml:mo><mml:mo>log</mml:mo><mml:mfenced close=")" open="("><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">sim</mml:mi></mml:mrow></mml:msubsup></mml:mfenced></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="280_2021_4305_Article_Equ19.gif"/></alternatives></disp-formula></p></sec><sec id="Sec12"><title>Results</title><p id="Par45">The regression procedure entailed a number of preliminary consecutive 4-dimension grid searches in a wide range of values (<italic toggle="yes">i.e.</italic> 1.E-08-1.E0), to identify a suitable starting point for an unconstrained minimization of the objective function. We carried out a 500-sample bootstrap analysis by resampling the 56 patients of the identification dataset and running a non-linear regression for each bootstrap sample. We obtained an approximately normal distribution for each fitted parameter and identified their mean value and standard deviation (Table <xref rid="Tab2" ref-type="table">2</xref>). The mean identified parameters lead to an objective function of 0.8568 for the identification dataset.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Regressed parameters values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Investigated range</th><th align="left" colspan="1" rowspan="1">Initial value</th><th align="left" colspan="1" rowspan="1">Mean fitted value</th><th align="left" colspan="1" rowspan="1">Standard deviation</th><th align="left" colspan="1" rowspan="1">Units</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq106"><alternatives><tex-math id="M231">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M232"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq106.gif"/></alternatives></inline-formula></td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.E-08&#8211;1.E0</td><td align="left" colspan="1" rowspan="1">2.1544E-02</td><td align="left" colspan="1" rowspan="1">1.5782E-03</td><td align="left" colspan="1" rowspan="1">2.3759E-04</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq107"><alternatives><tex-math id="M233">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M234"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq107.gif"/></alternatives></inline-formula></td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.E-08&#8211;1.E0</td><td align="left" colspan="1" rowspan="1">2.1544E-02</td><td align="left" colspan="1" rowspan="1">5.1829E-03</td><td align="left" colspan="1" rowspan="1">2.6271E-04</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq108"><alternatives><tex-math id="M235">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M236"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq108.gif"/></alternatives></inline-formula></td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.E-08&#8211;1.E0</td><td align="left" colspan="1" rowspan="1">3.1623E-07</td><td align="left" colspan="1" rowspan="1">2.4088E-07</td><td align="left" colspan="1" rowspan="1">2.9131E-08</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq109"><alternatives><tex-math id="M237">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M238"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq109.gif"/></alternatives></inline-formula></td><td char="&#x2013;" align="char" colspan="1" rowspan="1">1.E-08&#8211;1.E0</td><td align="left" colspan="1" rowspan="1">3.1622E-06</td><td align="left" colspan="1" rowspan="1">5.6171E-06</td><td align="left" colspan="1" rowspan="1">1.1798E-06</td><td align="left" colspan="1" rowspan="1">min<sup>&#8722;1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"><inline-formula id="IEq110"><alternatives><tex-math id="M239">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ObjFun$$\end{document}</tex-math><mml:math id="M240"><mml:mrow><mml:mi mathvariant="italic">ObjFun</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq110.gif"/></alternatives></inline-formula></td><td char="&#x2013;" align="char" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.2839E0</td><td align="left" colspan="1" rowspan="1">8.5684E-01</td><td align="left" colspan="1" rowspan="1">1.0909E-01</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table></table-wrap></p><p id="Par46">The identified parameters allow to numerically assess the <inline-formula id="IEq66"><alternatives><tex-math id="M241">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{k_{CS \to ISF} } \mathord{\left/ {\vphantom {{k_{CS \to ISF} } {k_{ISF \to CS} }}} \right. \kern-\nulldelimiterspace} {k_{ISF \to CS} }}$$\end{document}</tex-math><mml:math id="M242"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true">/</mml:mo></mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq66.gif"/></alternatives></inline-formula> ratio, which is equal to 0.3045 and might result from the compensation of errors of CS/ISF protein binding and volume estimates. The ratio agrees with the expected order of magnitude, <italic toggle="yes">i.e.</italic> around unity.</p><p id="Par47">The simulation of the validation dataset featuring the remaining 28 patients yielded an objective function of 0.8175 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a), which is close to the one produced by the identification procedure (0.8568).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Model predicted vs observed concentration plots for <bold>a</bold> our minimal PBPK model (ObjFun&#8201;=&#8201;0.8175) and <bold>b</bold> the 2-compartment pharmacokinetic model of Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>] (ObjFun&#8201;=&#8201;1.0799). For each experimental plasma concentration (<italic toggle="yes">x</italic>-axis), the diagrams show the corresponding simulated value (y-axis)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="280_2021_4305_Fig2_HTML.jpg"/></fig></p><p id="Par48">These results are compared with the simulations of a 2-compartment pharmacokinetic model used in many literature MTX studies, applied by Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>] to the same experimental dataset (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). For the same dataset used to validate our minimal PBPK model, the 2-compartment simulation yields an objective function of 1.0799.</p><p id="Par49">Figure <xref rid="Fig3" ref-type="fig">3</xref>a-f shows an analysis performed according to the specific conditions of the patients at each specific time, for sex, body weight, GFR, blood protein levels, age, and length of treatment. All the characteristic values are classified according to their distribution as low (0&#8211;25 percentiles), medium (26&#8211;75 percentiles), and high (76&#8211;100 percentiles).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Model predicted vs observed concentration plots that highlight the conditions of each experimental point, according to <bold>a</bold> gender, <bold>b</bold> body weight, <bold>c</bold> GFR, <bold>d</bold> total blood proteins, <bold>e</bold> age, <bold>f</bold> length of treatment</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="280_2021_4305_Fig3_HTML.jpg"/></fig></p><p id="Par50">The predicted overall MTX clearance, estimated as <inline-formula id="IEq67"><alternatives><tex-math id="M243">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\left( {\dot{m}_{excretion}^{renal} + \dot{m}_{elimination}^{hepatic} } \right)/c_{CS}^{u}$$\end{document}</tex-math><mml:math id="M244"><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">excretion</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">renal</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#729;</mml:mo></mml:mover><mml:mrow><mml:mi mathvariant="italic">elimination</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">hepatic</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:msubsup><mml:mi>c</mml:mi><mml:mrow><mml:mi mathvariant="italic">CS</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msubsup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq67.gif"/></alternatives></inline-formula>, approximately follows a normal distribution (mean 92.5&#160;ml/min, range 44&#8211;149&#160;ml/min, coefficient of variation 21%) for the 84 patients in the dataset.</p><p id="Par51">Figure <xref rid="Fig4" ref-type="fig">4</xref> shows the simulated curves for a specific section of the clinical data of patient 630.3, whose objective function (0.5416) corresponds to the median value within the validation dataset. The 200-h section includes three close, consecutive infusions and is deemed as representative of the whole dataset and useful to discuss the consistency of model predictions and their limitations.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Simulated curves for patient 630.3 with median error (ObjFun&#8201;=&#8201;0.5416): <bold>a</bold> infusion rates, <bold>b</bold> estimated GFR, <bold>c</bold>-<bold>d</bold> simulated and experimental CS concentrations (in linear and logarithmic coordinates), <bold>e</bold> comparison of CS, ISF and ICF concentrations, <bold>f</bold> comparison of drug amounts in the overall plasma (CS&#8201;+&#8201;RCS&#8201;+&#8201;HCS), ISF, and ICF</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="280_2021_4305_Fig4_HTML.jpg"/></fig></p><p id="Par52">Despite the wide range of experimental concentrations, as can be seen from both Fig. <xref rid="Fig4" ref-type="fig">4</xref>c and d, the drug levels measured by Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>] never capture the peak following HDMTX administration. In fact, while the drug administrations started between 9:45 AM and 11:15 PM, and finished in most cases before midnight (at most at 3:30 AM of the following day), the blood samples for MTX analysis were always taken between 5&#160;AM and 6&#160;AM, <italic toggle="yes">i.e.</italic> hours later.</p><p id="Par53">The model describes ICF concentrations that reach peaks of 0.2&#8211;0.3&#160;&#181;g/mL, <italic toggle="yes">i.e.</italic> 0.44&#8211;0.66&#160;&#181;M. Indeed, the ICF compartment acts as an MTX reservoir that becomes significant when plasma MTX levels fall below 0.1&#160;&#181;M.</p><p id="Par54">At concentrations lower than 0.1&#160;&#181;M, the simulations show a steady and very slow decrease of ICF concentration. As a result, the linear trend (in logarithmic coordinates of Fig. <xref rid="Fig4" ref-type="fig">4</xref>d) of plasma concentration is interrupted at about 0.1&#160;&#181;M and a new quasi-linear (<italic toggle="yes">i.e.</italic> approximately exponential in linear coordinates) decrease can be observed, which is much slower, with a half time of about 40&#160;h.</p></sec><sec id="Sec13"><title>Discussion</title><p id="Par55">Four population parameters of the model are identified with a bootstrap analysis and non-linear regressions of individual experimental data that describe a population of patients suffering from PCNSL. The values of the <inline-formula id="IEq68"><alternatives><tex-math id="M245">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{CS \to ISF}$$\end{document}</tex-math><mml:math id="M246"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq68.gif"/></alternatives></inline-formula> and <inline-formula id="IEq69"><alternatives><tex-math id="M247">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to CS}$$\end{document}</tex-math><mml:math id="M248"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>C</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq69.gif"/></alternatives></inline-formula> constants determine low <inline-formula id="IEq70"><alternatives><tex-math id="M249">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$K_{CS \to ISF} /Q_{CO}^{plasma}$$\end{document}</tex-math><mml:math id="M250"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>S</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi mathvariant="italic">CO</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">plasma</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq70.gif"/></alternatives></inline-formula> fractions, in the 0.4&#8211;0.8% range, which suggests permeability-limited capillary exchange and distribution [<xref ref-type="bibr" rid="CR26">26</xref>]. Despite its molecule being relatively small (454&#160;g/mol), MTX is hydrophilic and has limited lipid solubility [<xref ref-type="bibr" rid="CR15">15</xref>]. As for <inline-formula id="IEq71"><alternatives><tex-math id="M251">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M252"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq71.gif"/></alternatives></inline-formula> and <inline-formula id="IEq72"><alternatives><tex-math id="M253">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M254"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq72.gif"/></alternatives></inline-formula>, the maximum efflux rate <inline-formula id="IEq73"><alternatives><tex-math id="M255">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ICF \to ISF}^{max}$$\end{document}</tex-math><mml:math id="M256"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq73.gif"/></alternatives></inline-formula> is higher than the cellular uptake rate <inline-formula id="IEq74"><alternatives><tex-math id="M257">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ISF \to ICF}^{max}$$\end{document}</tex-math><mml:math id="M258"><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>S</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false">&#8594;</mml:mo><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">max</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="280_2021_4305_Article_IEq74.gif"/></alternatives></inline-formula>, in agreement with [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par56">The model is validated against a different set of patients from the same dataset. Figure <xref rid="Fig2" ref-type="fig">2</xref> shows a wide distribution across the bisector. Indeed, the literature reports a very large intra- and inter-individual variability in the case of HDMTX treatment [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>], and also Mei et al. [<xref ref-type="bibr" rid="CR41">41</xref>] label this variability as &#8220;extremely large&#8221;. Despite this, results suggest that the identified parameters are capable of capturing the average pharmacokinetic behavior of the diseased population. The comparison with a pharmacokinetic model used in several literature studies (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b) also shows that, despite the rigid prior estimation of compartment volumes and clearance flows, the minimal PBPK model predictions appear to better account for the wide experimental variability of the dataset.</p><p id="Par57">We investigated the model predictions against sex, weight, GFR, protein levels, or age (Fig. <xref rid="Fig3" ref-type="fig">3</xref>a-e) and found no indication of any clear systematic error. Remarkably, the model does not present any significant bias in a wide range of degrees of renal function, with estimated GFR values ranging from 35&#160;mL/min to 162&#160;mL/min (39&#160;&#160;mL/min/1.73 m<sup>2</sup> to 150&#160;mL/min/1.73 m<sup>2</sup>) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>c). This is expected to favor the application of the model to special populations with different characteristics, such as people with renal impairment. Conversely, when treatment length is medium (40&#8211;111&#160;days) or high (111&#8211;325&#160;days), model predictions appear to slightly underestimate the higher concentration values (Fig. <xref rid="Fig3" ref-type="fig">3</xref>f). This might indicate renal impairment arising with repeated administrations of HDMTX, as reported by [<xref ref-type="bibr" rid="CR47">47</xref>]. Despite these findings, however, we did not impose a kidney function decline in our model. While the hypothesis of renal impairment is consistent with reports from the literature [<xref ref-type="bibr" rid="CR47">47</xref>], the observed effect might be due to other factors, <italic toggle="yes">e.g.</italic> comedications such as dexamethasone, or also to a selection bias (patients who undergo longer treatments are ill patients who have not recovered yet despite multiple HDMTX cycles).</p><p id="Par58">Finally, we described an intracellular fluid compartment characterized by slow saturable exchanges, which determines the prediction of a slow MTX decrease at low plasma concentrations (in the 0.001&#8211;0.1&#160;&#181;M range). The overall predicted behavior appears generally consistent with the reference trend of MTX decay in Abelson et al. [<xref ref-type="bibr" rid="CR48">48</xref>]. Further studies are recommended to improve the modeling of cellular uptake, efflux, and other intracellular phenomena.</p><p id="Par59">We presented the development, identification, and validation of a minimal PBPK model of i.v. HDMTX methotrexate for adult patients. The model lumps the organs and tissues of the human body, and explicitly describes distinct compartments for plasma, interstitial fluid, and intracellular fluid. Since renal excretion is the main elimination route for methotrexate, the model is extended with a detailed description of renal excretion according to an anatomical and physiological approach. The model accounts for the specific characteristics and clinical data of each patient. Individual features such as body weight, height, gender, age, hematocrit, and serum creatinine are used to estimate a priori the pharmacokinetic parameters of each patient. This allows obtaining individualized predictions of MTX pharmacokinetics as a function of i.v. HDMTX administrations.</p><p id="Par60">The model was developed using a dataset of Chinese patients with PCNSL and can be generalized to other populations by employing a suitable equation to estimate the GFR and by describing the different features of the target population, <italic toggle="yes">e.g.</italic> body volumes and protein binding.</p><p id="Par61">Future developments should attempt to account for the residual intra- and inter-individual variability, especially by improving the estimation of volumes and exchanges as a function of further patient&#8217;s features. In addition, model identification and validation should be replicated using different experimental datasets, possibly including patients with severe renal impairment, describing peak concentrations, and focusing on different populations and therapeutic protocols.</p><p id="Par62">We believe that our model can be used to propose better individualized dosages and schedules of HDMTX, support the therapeutic monitoring of patients, and lead to better clinical treatment.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge the valuable contribution of Zhigang Zhao, Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China, for his quick and helpful clarifications about the experimental dataset.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Politecnico di Milano within the CRUI-CARE Agreement.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par63">The authors declare that they do not have any conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>ADR</given-names></name><name name-style="western"><surname>Illerhaus</surname><given-names>G</given-names></name><name name-style="western"><surname>Ferreri</surname><given-names>AJM</given-names></name></person-group><article-title>Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma</article-title><source>Leuk Lymphoma</source><year>2012</year><volume>53</volume><issue>10</issue><fpage>1867</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.3109/10428194.2012.676177</pub-id><pub-id pub-id-type="pmid">22530664</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>SC</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>J</given-names></name><name name-style="western"><surname>Pui</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Buddington</surname><given-names>RK</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>RD</given-names></name></person-group><article-title>Preventing and managing toxicities of high-dose methotrexate</article-title><source>Oncologist</source><year>2016</year><volume>21</volume><fpage>1471</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2015-0164</pub-id><pub-id pub-id-type="pmid">27496039</pub-id><pub-id pub-id-type="pmcid">PMC5153332</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grommes</surname><given-names>C</given-names></name><name name-style="western"><surname>DeAngelis</surname><given-names>LM</given-names></name></person-group><article-title>Primary CNS lymphoma</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><issue>21</issue><fpage>2410</fpage><lpage>2418</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.72.7602</pub-id><pub-id pub-id-type="pmid">28640701</pub-id><pub-id pub-id-type="pmcid">PMC5516483</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Treon</surname><given-names>S</given-names></name><name name-style="western"><surname>Chabner</surname><given-names>B</given-names></name></person-group><article-title>Concepts in use of high-dose methotrexate therapy</article-title><source>Clin Chem</source><year>1996</year><volume>42</volume><issue>8</issue><fpage>1322</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1093/clinchem/42.8.1322</pub-id><pub-id pub-id-type="pmid">8697606</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comandone</surname><given-names>A</given-names></name><name name-style="western"><surname>Passera</surname><given-names>R</given-names></name><name name-style="western"><surname>Boglione</surname><given-names>A</given-names></name><name name-style="western"><surname>Tagini</surname><given-names>V</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>S</given-names></name><name name-style="western"><surname>Cattel</surname><given-names>L</given-names></name></person-group><article-title>High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results</article-title><source>Acta Oncol</source><year>2005</year><volume>44</volume><issue>4</issue><fpage>406</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1080/02841860510029770</pub-id><pub-id pub-id-type="pmid">16120550</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santisteban</surname><given-names>M</given-names></name><name name-style="western"><surname>Nieto</surname><given-names>Y</given-names></name><name name-style="western"><surname>De la Cruz</surname><given-names>S</given-names></name><name name-style="western"><surname>Aristu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zubieta</surname><given-names>J</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>OF</given-names></name></person-group><article-title>Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule</article-title><source>Clin Transl Oncol</source><year>2007</year><volume>9</volume><issue>7</issue><fpage>465</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1007/s12094-007-0086-4</pub-id><pub-id pub-id-type="pmid">17652061</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuhara</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Kumagai</surname><given-names>K</given-names></name></person-group><article-title>Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data</article-title><source>J Clin Pharm Ther</source><year>2008</year><volume>33</volume><issue>6</issue><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2008.00966.x</pub-id><pub-id pub-id-type="pmid">19138246</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graf</surname><given-names>N</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>K</given-names></name><name name-style="western"><surname>Betlemovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>N</given-names></name><name name-style="western"><surname>Bode</surname><given-names>U</given-names></name></person-group><article-title>Methotrexate pharmacokinetics and prognosis in osteosarcoma</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><issue>7</issue><fpage>1443</fpage><lpage>1451</lpage><pub-id pub-id-type="doi">10.1200/JCO.1994.12.7.1443</pub-id><pub-id pub-id-type="pmid">8021736</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferreri</surname><given-names>AJM</given-names></name><name name-style="western"><surname>Kr&#228;henb&#252;hl</surname><given-names>S</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JHM</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>T</given-names></name><name name-style="western"><surname>Zucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>ADR</given-names></name></person-group><article-title>Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate</article-title><source>Br J Clin Pharmacol</source><year>2012</year><volume>73</volume><issue>2</issue><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.04084.x</pub-id><pub-id pub-id-type="pmid">21838788</pub-id><pub-id pub-id-type="pmcid">PMC3269583</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Widemann</surname><given-names>BC</given-names></name><name name-style="western"><surname>Adamson</surname><given-names>PC</given-names></name></person-group><article-title>Understanding and managing methotrexate nephrotoxicity</article-title><source>Oncologist</source><year>2006</year><volume>11</volume><issue>6</issue><fpage>694</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.11-6-694</pub-id><pub-id pub-id-type="pmid">16794248</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiczer</surname><given-names>T</given-names></name><name name-style="western"><surname>Dotson</surname><given-names>E</given-names></name><name name-style="western"><surname>Tuten</surname><given-names>A</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>G</given-names></name><name name-style="western"><surname>Maddocks</surname><given-names>K</given-names></name></person-group><article-title>Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity</article-title><source>J Oncol Pharm Pract</source><year>2016</year><volume>22</volume><issue>3</issue><fpage>430</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1177/1078155215594417</pub-id><pub-id pub-id-type="pmid">26152702</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abrey</surname><given-names>LE</given-names></name></person-group><article-title>Hematology: individualized methotrexate dosing in primary CNS lymphoma</article-title><source>Nat Rev Clin Oncol</source><year>2010</year><volume>7</volume><issue>6</issue><fpage>306</fpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2010.66</pub-id><pub-id pub-id-type="pmid">20517339</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreri</surname><given-names>AJM</given-names></name><name name-style="western"><surname>Reni</surname><given-names>M</given-names></name><name name-style="western"><surname>Foppoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Martelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Pangalis</surname><given-names>GA</given-names></name><name name-style="western"><surname>Frezzato</surname><given-names>M</given-names></name><name name-style="western"><surname>Cabras</surname><given-names>MG</given-names></name><name name-style="western"><surname>Fabbri</surname><given-names>A</given-names></name><name name-style="western"><surname>Corazzelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Ilariucci</surname><given-names>F</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G</given-names></name><name name-style="western"><surname>Soffietti</surname><given-names>R</given-names></name><name name-style="western"><surname>Stelitano</surname><given-names>C</given-names></name><name name-style="western"><surname>Vallisa</surname><given-names>D</given-names></name><name name-style="western"><surname>Zaja</surname><given-names>F</given-names></name><name name-style="western"><surname>Zoppegno</surname><given-names>L</given-names></name><name name-style="western"><surname>Aondio</surname><given-names>GM</given-names></name><name name-style="western"><surname>Avvisati</surname><given-names>G</given-names></name><name name-style="western"><surname>Balzarotti</surname><given-names>M</given-names></name><name name-style="western"><surname>Brandes</surname><given-names>AA</given-names></name><name name-style="western"><surname>Fajardo</surname><given-names>J</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>H</given-names></name><name name-style="western"><surname>Guarini</surname><given-names>A</given-names></name><name name-style="western"><surname>Pinotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Rigacci</surname><given-names>L</given-names></name><name name-style="western"><surname>Uhlmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Picozzi</surname><given-names>P</given-names></name><name name-style="western"><surname>Vezzulli</surname><given-names>P</given-names></name><name name-style="western"><surname>Ponzoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Zucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Caligaris-Cappio</surname><given-names>F</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>F</given-names></name></person-group><article-title>High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial</article-title><source>The Lancet</source><year>2009</year><volume>374</volume><issue>9700</issue><fpage>1512</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61416-1</pub-id><pub-id pub-id-type="pmid">19767089</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Bongard</surname><given-names>HD</given-names></name><name name-style="western"><surname>Math&#244;t</surname><given-names>RA</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JH</given-names></name></person-group><article-title>Pharmacokinetically guided administration of chemotherapeutic agents</article-title><source>Clin Pharmacokinet</source><year>2000</year><volume>39</volume><issue>5</issue><fpage>345</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.2165/00003088-200039050-00004</pub-id><pub-id pub-id-type="pmid">11108434</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grim</surname><given-names>J</given-names></name><name name-style="western"><surname>Chl&#225;dek</surname><given-names>J</given-names></name><name name-style="western"><surname>Mart&#237;nkov&#225;</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases</article-title><source>Clin Pharmacokinet</source><year>2003</year><volume>42</volume><issue>2</issue><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.2165/00003088-200342020-00003</pub-id><pub-id pub-id-type="pmid">12537514</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>A</given-names></name><name name-style="western"><surname>Kr&#228;henb&#252;hl</surname><given-names>S</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>J</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>T</given-names></name><name name-style="western"><surname>Reni</surname><given-names>M</given-names></name><name name-style="western"><surname>Zucca</surname><given-names>E</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferreri</surname><given-names>A</given-names></name></person-group><article-title>Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic&#8211;pharmacodynamic analysis from the IELSG no. 20 trial</article-title><source>Br J Cancer</source><year>2010</year><volume>102</volume><issue>4</issue><fpage>673</fpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605559</pub-id><pub-id pub-id-type="pmid">20125159</pub-id><pub-id pub-id-type="pmcid">PMC2837574</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kintzel</surname><given-names>PE</given-names></name><name name-style="western"><surname>Dorr</surname><given-names>RT</given-names></name></person-group><article-title>Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function</article-title><source>Cancer Treat Rev</source><year>1995</year><volume>21</volume><issue>1</issue><fpage>33</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/0305-7372(95)90010-1</pub-id><pub-id pub-id-type="pmid">7859226</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pignon</surname><given-names>T</given-names></name><name name-style="western"><surname>Lacarelle</surname><given-names>B</given-names></name><name name-style="western"><surname>Duffaud</surname><given-names>F</given-names></name><name name-style="western"><surname>Guillet</surname><given-names>P</given-names></name><name name-style="western"><surname>Catalin</surname><given-names>J</given-names></name><name name-style="western"><surname>Durand</surname><given-names>A</given-names></name><name name-style="western"><surname>Monjanel</surname><given-names>S</given-names></name><name name-style="western"><surname>Favre</surname><given-names>R</given-names></name></person-group><article-title>Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma</article-title><source>Cancer Chemother Pharmacol</source><year>1994</year><volume>33</volume><issue>5</issue><fpage>420</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1007/bf00686272</pub-id><pub-id pub-id-type="pmid">8306417</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>WE</given-names></name><name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name><name name-style="western"><surname>Rodman</surname><given-names>JH</given-names></name><name name-style="western"><surname>Crom</surname><given-names>WR</given-names></name><name name-style="western"><surname>Boyett</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pui</surname><given-names>C-H</given-names></name></person-group><article-title>Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><issue>8</issue><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1056/nejm199802193380803</pub-id><pub-id pub-id-type="pmid">9468466</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W-q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L-y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X-y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>B-h</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J-q</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J-y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y-m</given-names></name></person-group><article-title>Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies</article-title><source>Cancer Chemother Pharmacol</source><year>2014</year><volume>73</volume><issue>1</issue><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00280-013-2319-2</pub-id><pub-id pub-id-type="pmid">24158402</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bischoff</surname><given-names>KB</given-names></name><name name-style="western"><surname>Dedrick</surname><given-names>RL</given-names></name><name name-style="western"><surname>Zaharko</surname><given-names>DS</given-names></name></person-group><article-title>Preliminary model for methotrexate pharmacokinetics</article-title><source>J Pharm Sci</source><year>1970</year><volume>59</volume><issue>2</issue><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1002/jps.2600590203</pub-id><pub-id pub-id-type="pmid">5411336</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaharko</surname><given-names>DS</given-names></name><name name-style="western"><surname>Dedrick</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>KB</given-names></name><name name-style="western"><surname>Longstreth</surname><given-names>JA</given-names></name><name name-style="western"><surname>Oliverio</surname><given-names>VT</given-names></name></person-group><article-title>Methotrexate tissue distribution: prediction by a mathematical model</article-title><source>JNCI</source><year>1971</year><volume>46</volume><issue>4</issue><fpage>775</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1093/jnci/46.4.775</pub-id><pub-id pub-id-type="pmid">5573769</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bischoff</surname><given-names>KB</given-names></name><name name-style="western"><surname>Dedrick</surname><given-names>RL</given-names></name><name name-style="western"><surname>Zaharko</surname><given-names>DS</given-names></name><name name-style="western"><surname>Longstreth</surname><given-names>JA</given-names></name></person-group><article-title>Methotrexate pharmacokinetics</article-title><source>J Pharm Sci</source><year>1971</year><volume>60</volume><issue>8</issue><fpage>1128</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1002/jps.2600600803</pub-id><pub-id pub-id-type="pmid">5127083</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dedrick</surname><given-names>RL</given-names></name><name name-style="western"><surname>Zaharko</surname><given-names>DS</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>RJ</given-names></name></person-group><article-title>Transport and binding of methotrexate in vivo</article-title><source>J Pharm Sci</source><year>1973</year><volume>62</volume><issue>6</issue><fpage>882</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1002/jps.2600620603</pub-id><pub-id pub-id-type="pmid">4712617</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogungbenro</surname><given-names>K</given-names></name><name name-style="western"><surname>Aarons</surname><given-names>L</given-names></name><collab>CRESim T, Groups E-CP</collab></person-group><article-title>Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children Part 1 methotrexate</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2014</year><volume>41</volume><issue>2</issue><fpage>159</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1007/s10928-014-9354-4</pub-id><pub-id pub-id-type="pmid">24651961</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jusko</surname><given-names>WJ</given-names></name></person-group><article-title>Applications of minimal physiologically-based pharmacokinetic models</article-title><source>J Pharmacokinet Pharmacodyn</source><year>2012</year><volume>39</volume><issue>6</issue><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1007/s10928-012-9280-2</pub-id><pub-id pub-id-type="pmid">23179857</pub-id><pub-id pub-id-type="pmcid">PMC3539784</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbiati</surname><given-names>RA</given-names></name><name name-style="western"><surname>Lamberti</surname><given-names>G</given-names></name><name name-style="western"><surname>Grassi</surname><given-names>M</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>F</given-names></name><name name-style="western"><surname>Manca</surname><given-names>D</given-names></name></person-group><article-title>Definition and validation of a patient-individualized physiologically-based pharmacokinetic model</article-title><source>Comput Chem Eng</source><year>2016</year><volume>84</volume><fpage>394</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.compchemeng.2015.09.018</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valentin</surname><given-names>J</given-names></name></person-group><article-title>Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89</article-title><source>Ann ICRP</source><year>2002</year><volume>32</volume><issue>3&#8211;4</issue><fpage>1</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/S0146-6453(03)00002-2</pub-id><pub-id pub-id-type="pmid">14506981</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritz</surname><given-names>P</given-names></name><name name-style="western"><surname>Vol</surname><given-names>S</given-names></name><name name-style="western"><surname>Berrut</surname><given-names>G</given-names></name><name name-style="western"><surname>Tack</surname><given-names>I</given-names></name><name name-style="western"><surname>Arnaud</surname><given-names>M</given-names></name><name name-style="western"><surname>Tichet</surname><given-names>J</given-names></name></person-group><article-title>Influence of gender and body composition on hydration and body water spaces</article-title><source>Clin Nutr</source><year>2008</year><volume>27</volume><issue>5</issue><fpage>740</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2008.07.010</pub-id><pub-id pub-id-type="pmid">18774628</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stader</surname><given-names>F</given-names></name><name name-style="western"><surname>Siccardi</surname><given-names>M</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M</given-names></name><name name-style="western"><surname>Kinvig</surname><given-names>H</given-names></name><name name-style="western"><surname>Penny</surname><given-names>MA</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C</given-names></name></person-group><article-title>Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes</article-title><source>Clin Pharmacokinet</source><year>2019</year><volume>58</volume><issue>4</issue><fpage>483</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1007/s40262-018-0709-7</pub-id><pub-id pub-id-type="pmid">30128967</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiehn</surname><given-names>C</given-names></name></person-group><article-title>Methotrexate transport mechanisms: the basis for targeted drug delivery and ss-folate-receptor-specific treatment</article-title><source>Clin Exp Rheumatol</source><year>2010</year><volume>28</volume><issue>5 Suppl 61</issue><fpage>S40</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21044432</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tirumalai</surname><given-names>RS</given-names></name><name name-style="western"><surname>Chan</surname><given-names>KC</given-names></name><name name-style="western"><surname>Prieto</surname><given-names>DA</given-names></name><name name-style="western"><surname>Issaq</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Conrads</surname><given-names>TP</given-names></name><name name-style="western"><surname>Veenstra</surname><given-names>TD</given-names></name></person-group><article-title>Characterization of the low molecular weight human serum proteome</article-title><source>Mol Cell Proteomics</source><year>2003</year><volume>2</volume><issue>10</issue><fpage>1096</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1074/mcp.M300031-MCP200</pub-id><pub-id pub-id-type="pmid">12917320</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raveendran</surname><given-names>R</given-names></name><name name-style="western"><surname>Heybroek</surname><given-names>W</given-names></name><name name-style="western"><surname>Caulfield</surname><given-names>M</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>M</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>SM</given-names></name><name name-style="western"><surname>Wrigley</surname><given-names>PF</given-names></name><name name-style="western"><surname>Slevin</surname><given-names>M</given-names></name><name name-style="western"><surname>Turner</surname><given-names>P</given-names></name></person-group><article-title>Indomethacin and protein binding of methotrexate</article-title><source>Hum Exp Toxicol</source><year>1992</year><volume>11</volume><issue>4</issue><fpage>291</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1177/096032719201100411</pub-id><pub-id pub-id-type="pmid">1354980</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sloop</surname><given-names>CH</given-names></name><name name-style="western"><surname>Dory</surname><given-names>L</given-names></name><name name-style="western"><surname>Roheim</surname><given-names>PS</given-names></name></person-group><article-title>Interstitial fluid lipoproteins</article-title><source>J Lipid Res</source><year>1987</year><volume>28</volume><issue>3</issue><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/S0022-2275(20)38701-0</pub-id><pub-id pub-id-type="pmid">3553402</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>W</given-names></name></person-group><article-title>General approach for the calculation of tissue to plasma partition coefficients</article-title><source>Toxicol In Vitro</source><year>2008</year><volume>22</volume><issue>2</issue><fpage>457</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2007.09.010</pub-id><pub-id pub-id-type="pmid">17981004</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christophidis</surname><given-names>N</given-names></name><name name-style="western"><surname>Louis</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>I</given-names></name><name name-style="western"><surname>Moon</surname><given-names>W</given-names></name><name name-style="western"><surname>Vajda</surname><given-names>FJ</given-names></name></person-group><article-title>Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy</article-title><source>Cancer Chemother Pharmacol</source><year>1981</year><volume>6</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/BF00253011</pub-id><pub-id pub-id-type="pmid">7273267</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Claybon</surname><given-names>MA</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Horio</surname><given-names>M</given-names></name><name name-style="western"><surname>Imai</surname><given-names>E</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>RG</given-names></name><name name-style="western"><surname>Van Deventer</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating the glomerular filtration rate in multiple ethnicities</article-title><source>Kidney Int</source><year>2011</year><volume>79</volume><issue>5</issue><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/ki.2010.462</pub-id><pub-id pub-id-type="pmid">21107446</pub-id><pub-id pub-id-type="pmcid">PMC4220293</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pottel</surname><given-names>H</given-names></name><name name-style="western"><surname>Delanaye</surname><given-names>P</given-names></name><name name-style="western"><surname>Weekers</surname><given-names>L</given-names></name><name name-style="western"><surname>Selistre</surname><given-names>L</given-names></name><name name-style="western"><surname>Goffin</surname><given-names>K</given-names></name><name name-style="western"><surname>Gheysens</surname><given-names>O</given-names></name><name name-style="western"><surname>Dubourg</surname><given-names>L</given-names></name></person-group><article-title>Age-dependent reference intervals for estimated and measured glomerular filtration rate</article-title><source>Clin Kidney J</source><year>2017</year><volume>10</volume><issue>4</issue><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1093/ckj/sfx026</pub-id><pub-id pub-id-type="pmid">28852494</pub-id><pub-id pub-id-type="pmcid">PMC5570001</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Widemann</surname><given-names>BC</given-names></name><name name-style="western"><surname>Sung</surname><given-names>E</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L</given-names></name><name name-style="western"><surname>Salzer</surname><given-names>WL</given-names></name><name name-style="western"><surname>Balis</surname><given-names>FM</given-names></name><name name-style="western"><surname>Monitjo</surname><given-names>KS</given-names></name><name name-style="western"><surname>McCully</surname><given-names>C</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>M</given-names></name><name name-style="western"><surname>Adamson</surname><given-names>PC</given-names></name></person-group><article-title>Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N10-methylpteroic Acid</article-title><source>J Pharmacol Exp Ther</source><year>2000</year><volume>294</volume><issue>3</issue><fpage>894</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">10945838</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seideman</surname><given-names>P</given-names></name><name name-style="western"><surname>Beck</surname><given-names>O</given-names></name><name name-style="western"><surname>Eksborg</surname><given-names>S</given-names></name><name name-style="western"><surname>Wennberg</surname><given-names>M</given-names></name></person-group><article-title>The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis</article-title><source>Br J Clin Pharmacol</source><year>1993</year><volume>35</volume><issue>4</issue><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1993.tb04158.x</pub-id><pub-id pub-id-type="pmid">8485020</pub-id><pub-id pub-id-type="pmcid">PMC1381552</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name></person-group><article-title>Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma</article-title><source>J Pharm Sci</source><year>2018</year><volume>107</volume><issue>5</issue><fpage>1454</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.01.004</pub-id><pub-id pub-id-type="pmid">29331383</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>MV</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kenyon</surname><given-names>EM</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>MF</given-names></name><name name-style="western"><surname>El-Masri</surname><given-names>HA</given-names></name></person-group><article-title>A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice</article-title><source>Toxicol Sci</source><year>2008</year><volume>104</volume><issue>2</issue><fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfn080</pub-id><pub-id pub-id-type="pmid">18430741</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poulin</surname><given-names>P</given-names></name><name name-style="western"><surname>Theil</surname><given-names>FP</given-names></name></person-group><article-title>A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery</article-title><source>J Pharm Sci</source><year>2000</year><volume>89</volume><issue>1</issue><fpage>16</fpage><lpage>35</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200001)89:1&amp;#x0003c;16::AID-JPS3&amp;#x0003e;3.0.CO;2-E</pub-id><pub-id pub-id-type="pmid">10664535</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name><name name-style="western"><surname>Yuasa</surname><given-names>H</given-names></name></person-group><article-title>Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy</article-title><source>Drug Metab Pharmacokinet</source><year>2014</year><volume>29</volume><issue>1</issue><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.2133/dmpk.DMPK-13-RV-119</pub-id><pub-id pub-id-type="pmid">24284432</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galivan</surname><given-names>J</given-names></name></person-group><article-title>Transport and metabolism of methotrexate in normal and resistant cultured rat hepatoma cells</article-title><source>Can Res</source><year>1979</year><volume>39</volume><issue>3</issue><fpage>735</fpage><pub-id pub-id-type="pmid">427761</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matherly</surname><given-names>LH</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>D</given-names></name></person-group><article-title>Membrane transport of folates</article-title><source>Vitam Horm</source><year>2003</year><volume>66</volume><fpage>405</fpage><lpage>457</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0083-6729(03)01012-4</pub-id><pub-id pub-id-type="pmid">12852262</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>MR</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>MC</given-names></name></person-group><article-title>Renal dysfunction during and after high-dose methotrexate</article-title><source>Cancer Chemother Pharmacol</source><year>2008</year><volume>63</volume><issue>4</issue><fpage>599</fpage><pub-id pub-id-type="doi">10.1007/s00280-008-0772-0</pub-id><pub-id pub-id-type="pmid">18504579</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abelson</surname><given-names>H</given-names></name><name name-style="western"><surname>Fosburg</surname><given-names>M</given-names></name><name name-style="western"><surname>Beardsley</surname><given-names>G</given-names></name><name name-style="western"><surname>Goorin</surname><given-names>A</given-names></name><name name-style="western"><surname>Gorka</surname><given-names>C</given-names></name><name name-style="western"><surname>Link</surname><given-names>M</given-names></name><name name-style="western"><surname>Link</surname><given-names>D</given-names></name></person-group><article-title>Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine</article-title><source>J Clin Oncol</source><year>1983</year><volume>1</volume><issue>3</issue><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1200/JCO.1983.1.3.208</pub-id><pub-id pub-id-type="pmid">6607976</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>